Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria

Journal of Rheumatology

Volumn 30, Issue 7, 2003, Pages 1648-1654

  Pham, Thao ^a,b   Der Heijde, Désirée Van ^c   Lassere, Marissa ^d   Altman, Roy D ^e   Anderson, Jennifer J ^f   Bellamy, Nicholas ^l   Hochberg, Marc ^g   Simon, Lee ^h   Strand, Vibeke ⁱ   Woodworth, Thasia ^j   Dougados, Maxime ^a,k  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIVERSITY OF MIAMI   (United States)

^f BOSTON MEDICAL CENTER   (United States)

^g UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁱ Biopharmaceutical Consultant   (United States)

^j PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^k NONE   (France)

^l NONE

more..

Author keywords

Clinical responder criteria; Osteoarthritis; Outcomes

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; STEROID;

ALGORITHM; CLINICAL FEATURE; CONFERENCE PAPER; HUMAN; OSTEOARTHRITIS; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; STANDARDIZATION; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE III; HEALTH STATUS INDICATORS; HUMANS; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 0038504818     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Altman RD, Hochberg MC. Degenerative joint disease. Clin Rheum Dis 1983;9:681-93.
2. Bellamy N, Kirwan J, Altman R, et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip and hand osteoarthritis. Results of consensus development at OMERACT III. J Rheumatol 1997;24:799-802.
3. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthrifis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039-49.
4. Hochberg MC, Altman RD, Brandt KD, Moskowitz RW, for the Task Force: Design and conduct of clinical trials in osteoarthritis: Preliminary recommendations from a task force of the Osteoarthritis Research Society. J Rheumatol 1997;24:792-4.
5. Carlsson AM. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain 1983;16:87-101.
6. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to anfirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40.
7. Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity for osteoarthritis of the hip and knee. Validation - value in comparison with other assessment tests. Scand J Rheumatol 1987;Suppl 65:85-9.
8. Felson DT, Anderson JJ, Boers M, et al: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
9. Dougados M, Leclaire P, van der Heijde D, Bloch DA, Bellamy N, Altman RD. Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative. Osteoarthritis Cart 2000;8:395-403.
10. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics 1984;40:1079-87.
11. Tilley BC, Pillemer SR, Heyse SP, Li S, Clegg DO, Alarcon GS. Global statistical tests for comparing multiple outcomes in rheumatoid arthritis trials. MIRA Trial Group. Arthritis Rheum 1999;42:1879-88.
12. Bolognese JA, Ehrich EW, Schnitzer TJ. Precision of composite measures of osteoarthritis efficacy in comparison to that of individual endpoints. J Rheumatol 2001;28:2700-4.